These guidelines contain policy recommendations on priority areas in the treatment of drug-susceptible TB and patient care.

The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.

This document provides recommendations on the use chest radiography in TB detection. Specifically, the document provides information on chest radiography as a triage tool, diagnostic aid, and a screening tool. Additionally, quality assurance, safety, strategic planning, and technological developments are discussed.

This infographic provides an overview of the global TB epidemic.

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This report is updated annually.

The WHO treatment guidelines for drug-resistant TB contains policy recommendations on priority areas in the treatment of drug-resistant TB.

These guidelines aim to reduce morbidity and mortality related to TB and HIV-associated TB among people who inject drugs (PWID) through the integrated delivery of a comprehensive and holistic package of care. The guidelines provide an update of the 2008 Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach.

This document highlights how the Ministries of Health of the 30 highest TB burden countries, and their partners, are beginning to adopt, adapt and implement the End TB Strategy.

This fact sheet provides information on the connection between TB and diabetes and outlines activities where TB and diabetes programs can collaborate.

This document shares best practices in engagement of health care providers in programmatic management of drug-resistant tuberculosis that have been documented in different countries and regions and implemented by different stakeholders. Case studies presented in the document are lessons learned for scale-up of public-private mix for the management of drug-resistant TB at country level.